Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ABMC gains CLIA waiver for Rapid TOX drug tests

This article was originally published in The Gray Sheet

Executive Summary

Kinderhook, N.Y.-based American Bio Medical Corp. says Aug. 27 it expects to see increased sales of the product line now that FDA has granted CLIA-waived status for the point-of-collection drug tests. The waiver includes the 14 drugs ABMC currently tests for, as well as new cut-off levels for its opiate and cocaine tests. While the Rapid TOX line tests for drug traces in urine, the company has other lines that test for drugs in oral fluids
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT026503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel